List of Excipients in Branded Drug AMITRIPTYLINE HYDROCHLORIDE

Generic Drugs Containing AMITRIPTYLINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	amitriptyline hydrochloride	0378-2610	CALCIUM SULFATE
Mylan Pharmaceuticals Inc	amitriptyline hydrochloride	0378-2610	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	amitriptyline hydrochloride	0378-2610	HYDROXYPROPYL CELLULOSE
Mylan Pharmaceuticals Inc	amitriptyline hydrochloride	0378-2610	HYPROMELLOSE
Mylan Pharmaceuticals Inc	amitriptyline hydrochloride	0378-2610	MAGNESIUM STEARATE
Mylan Pharmaceuticals Inc	amitriptyline hydrochloride	0378-2610	POLYETHYLENE GLYCOL

What are the Most Frequently-Used Excipients in AMITRIPTYLINE HYDROCHLORIDE?

# Of NDCs	Excipient
14	ALUMINUM OXIDE
2	CALCIUM SULFATE
5	CARMINIC ACID
232	CELLULOSE, MICROCRYSTALLINE
1	CI 15985
1	CI 47005

Amitriptyline Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

Amitriptyline hydrochloride is a mature, low-cost tricyclic antidepressant sold primarily as immediate-release oral tablets. Its core active-ingredient patents and regulatory exclusivities expired decades ago. Commercial opportunity therefore depends on formulation execution, channel access, patient adherence, supply reliability, and differentiated delivery formats rather than conventional molecule exclusivity.

The strongest opportunities are alcohol-free oral liquids, flexible low-dose products, orally disintegrating tablets, combination products, and formulations designed for geriatric, pediatric, dysphagia, or neuropathic-pain populations. Excipient selection must address dose uniformity, bitterness, stability, tablet swallowability, colorant sensitivity, and manufacturing cost.

What is the FDA regulatory status of amitriptyline hydrochloride?

Amitriptyline hydrochloride is an FDA-approved small-molecule drug available mainly as immediate-release tablets. It is indicated for the relief of symptoms of depression, although current clinical use also includes off-label treatment of neuropathic pain, migraine prevention, insomnia, and selected functional pain disorders.[1]

Regulatory attribute	Status
Active ingredient	Amitriptyline hydrochloride
Drug class	Tricyclic antidepressant
Primary route	Oral
Common dosage forms	Immediate-release tablets; compounded oral liquids
FDA pathway for established tablets	Abbreviated New Drug Application, or ANDA
Reference product	Elavil and historical equivalents
Biologic status	Not a biologic
Biosimilar pathway	Not applicable
Controlled-substance status	Not federally scheduled
Key safety considerations	Suicidality warning in younger patients, anticholinergic effects, sedation, orthostatic hypotension, cardiac conduction risk, overdose toxicity

Amitriptyline is not interchangeable with a biologic and does not create biosimilar exposure. Competition occurs through generic ANDAs, authorized generic supply, compounding, and potential 505(b)(2) reformulations.

The FDA labeling for amitriptyline hydrochloride tablets includes warnings related to use in children and young adults, cardiovascular effects, central nervous system effects, and potentially fatal overdose.[1] Those risks limit the commercial value of formulations that simply improve taste without adding meaningful dosing control or safety value.

What excipients are used in amitriptyline hydrochloride tablets?

Commercial tablet formulations use conventional excipients for direct compression, granulation, film coating, color differentiation, and protection from moisture and light. The exact composition differs by manufacturer and strength.

Common inactive ingredients reported in FDA labeling and product databases include:

Excipient category	Typical examples	Formulation function
Diluent	Lactose monohydrate, microcrystalline cellulose, dibasic calcium phosphate	Adds bulk and improves compressibility
Binder	Pregelatinized starch, povidone, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Starch, sodium starch glycolate, croscarmellose sodium	Promotes tablet breakup
Lubricant	Magnesium stearate, stearic acid	Reduces die-wall friction
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Coating agent	Hypromellose, polyethylene glycol, titanium dioxide	Controls appearance and handling
Colorant	FD&C dyes, D&C dyes, iron oxides	Enables strength identification
Opacifier	Titanium dioxide	Improves coating opacity and appearance

The principal excipient risks are not unusual chemical incompatibility. They are operational and commercial:

1. Lactose can exclude patients with intolerance concerns, although the quantity in a tablet is generally low.
2. Colorants can complicate procurement and create labeling or market-access issues.
3. Magnesium stearate and hydrophobic coating systems can slow dissolution if overused.
4. Talc and titanium dioxide can create customer or regional acceptance issues.
5. Starch and cellulose systems can vary in compression behavior across suppliers.
6. Low-dose tablets require tight blend uniformity because the active load is small.

Product-specific inactive ingredients must be confirmed against the target reference product and the FDA-approved labeling for the proposed strength. FDA DailyMed entries show that generic amitriptyline tablets do not use a single universal excipient formula.[2]

How should an excipient strategy be designed for amitriptyline hydrochloride?

The most defensible strategy is to select excipients around the intended patient segment rather than pursue a generic “clean label” claim.

Immediate-release tablets for cost-sensitive markets

For conventional tablets, the preferred formulation is a robust, low-cost direct-compression or dry-granulation platform using:

• Microcrystalline cellulose or lactose as the principal diluent
• Low levels of a superdisintegrant
• Magnesium stearate with controlled blending time
• Colloidal silicon dioxide for flow
• A thin film coat for identification and handling

The design target is rapid, reproducible dissolution rather than modified release. Amitriptyline hydrochloride is readily soluble in water, but finished-product dissolution still depends on tablet porosity, lubricant concentration, granulation density, and coating permeability.

Manufacturers should avoid unnecessary excipient complexity. A short formula reduces supplier qualification burden, analytical method burden, and batch-to-batch variability.

Lactose-free tablets

A lactose-free product can address hospital formularies, institutional procurement, and patients who avoid lactose-containing medicines. Microcrystalline cellulose, mannitol, or dibasic calcium phosphate can replace lactose.

The commercial value is limited if the product has no additional differentiation. Lactose-free positioning is more credible when combined with dye-free, low-allergen, or geriatric-friendly packaging.

Dye-free tablets

A dye-free formulation can reduce excipient concerns and simplify procurement for customers with colorant preferences. The tradeoff is that tablets become harder to distinguish by strength. That issue can be managed through shape, imprinting, embossing, blister segregation, and clear labeling.

Because amitriptyline is commonly available in multiple strengths, strength-identification controls are important. A dye-free portfolio should not rely on color alone.

Low-dose and geriatric formulations

Amitriptyline is often initiated at low doses and titrated. Low-strength tablets may therefore have greater practical value than high-strength products. Excipient and manufacturing priorities include:

• High content uniformity at low active concentration
• Low tablet mass variation
• Easy swallowing
• Consistent subdivision if scored
• Reduced friability
• Minimal powdering and breakage

A scored tablet requires evidence that splitting produces acceptable dose uniformity. A score line alone does not establish a commercially meaningful splitting claim.

What formulation opportunities exist for amitriptyline hydrochloride?

Alcohol-free oral solution

An oral liquid is one of the clearest opportunities for differentiation. It could address pediatric prescribing, dysphagia, feeding-tube administration, and dose titration.

Key development issues include:

• Solubility at the target concentration
• pH control
• Preservative efficacy
• Microbial limits
• Taste masking
• Container compatibility
• Dosing-device accuracy
• Stability after opening

Amitriptyline hydrochloride has a bitter taste. Sweeteners alone may not provide sufficient masking. A commercial liquid may require a combination of sweetener, flavor, viscosity modifier, and a bitterness-suppression system.

Potential excipients include sucrose or sugar-free polyols, glycerin, sorbitol, sucralose, flavor systems, citric acid or citrate buffers, and preservatives such as sodium benzoate or parabens. Each introduces tradeoffs. Sorbitol can cause gastrointestinal effects at higher exposure. Sugar-based systems are less suitable for some patients. Benzoate preservatives create concentration and labeling considerations.

An alcohol-free, sugar-free, dye-free liquid with a calibrated oral syringe would have stronger differentiation than a standard compounded syrup.

Orally disintegrating tablet

An orally disintegrating tablet, or ODT, could target patients with dysphagia and those who have difficulty swallowing conventional tablets. Mannitol, crospovidone, low-substituted hydroxypropyl cellulose, microcrystalline cellulose, and porous excipient systems are common platform choices.

The main technical risks are:

• Bitter taste before swallowing
• Tablet friability
• Moisture sensitivity
• Packaging cost
• Dose uniformity
• Disintegration performance under routine handling

Amitriptyline's bitter taste makes taste masking central to ODT development. A simple rapidly disintegrating tablet without taste control is unlikely to create durable commercial differentiation.

Multiparticulate or sprinkle formulation

A capsule containing coated pellets could support patients who cannot swallow tablets. The drug could be layered or granulated onto inert cores and coated with a taste-masking polymer.

The product would need clear administration instructions. Mixing with soft food may affect drug recovery, dose uniformity, or stability. The product also would need compatibility data for common vehicles and feeding-tube use if that population is targeted.

Modified-release formulation

A sustained-release formulation could reduce dosing frequency, but the commercial case is less straightforward. Amitriptyline has a long clinical history of once-daily bedtime administration, so a modified-release product must show a meaningful benefit over standard tablets.

Potential value propositions include reduced peak-related sedation, smoother exposure, or improved adherence. The development burden would include comparative pharmacokinetics, dose-dumping assessment, food-effect evaluation, and potentially a 505(b)(2) strategy.

A modified-release product could obtain new formulation claims if the formulation is novel and nonobvious. Those claims would not restore exclusivity to the underlying active ingredient.

What patents protect amitriptyline hydrochloride?

The original composition-of-matter and basic product protection for amitriptyline hydrochloride expired long ago. The current generic market is therefore based on expired active-ingredient rights and approved ANDA products.

The remaining patent opportunity is formulation-specific. Potential claim categories include:

• Orally disintegrating tablets
• Taste-masked particles
• Sustained-release matrices
• Stable oral solutions
• Specific salt, polymorph, or particle-size forms
• Combination products
• Manufacturing processes
• Device-assisted liquid delivery
• Narrow method-of-use claims

A new patent must satisfy novelty, nonobviousness, written description, enablement, and patentable subject-matter requirements. A patent directed only to routine substitution of one standard diluent for another would face a significant obviousness risk.

What is the Orange Book status of amitriptyline hydrochloride?

The FDA Orange Book is relevant to approved listed drugs and patent certifications for ANDA applicants.[3] For mature amitriptyline hydrochloride tablet products, the commercial landscape is primarily generic and does not depend on an active composition-of-matter patent.

Any proposed reformulation should be checked against current Orange Book listings and FDA labeling at the time of filing. A reformulated product may be listed differently from a conventional generic, depending on the approval pathway and whether it references a listed drug.

When does amitriptyline hydrochloride lose exclusivity?

Amitriptyline hydrochloride lost core market exclusivity decades ago. There is no current innovator exclusivity comparable to the protection attached to a newly approved small molecule.

Exclusivity category	Commercial position
Composition-of-matter patent	Expired
Original product patent	Expired
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current strategic relevance
Orphan-drug exclusivity	Not applicable to standard amitriptyline use
Generic competition	Established
New formulation protection	Possible only through new patentable technology
180-day generic exclusivity	Relevant only to a qualifying ANDA challenge to a listed patent

A reformulated product could create a new protection period only through an approved regulatory pathway and valid new intellectual property. It would not re-establish exclusivity for ordinary amitriptyline tablets.

Are there Paragraph IV challenges for amitriptyline hydrochloride?

Paragraph IV certifications are used when an ANDA applicant asserts that a listed patent is invalid, unenforceable, or will not be infringed.[4] They are most relevant when an innovator or reformulator has listed a current patent in the Orange Book.

For standard immediate-release amitriptyline hydrochloride tablets, the practical Paragraph IV exposure is limited because the underlying active-ingredient rights are expired and the product has long been genericized. A future reformulation with Orange Book-listed patents could generate Paragraph IV litigation, particularly if the patent covers a commercially attractive liquid, ODT, or extended-release dosage form.

A patent owner considering an amitriptyline reformulation should expect challenges if the product achieves meaningful sales. Patent claims should be tied to measurable formulation attributes and supported by comparative data.

Which companies are challenging amitriptyline hydrochloride patents?

The market has historically included multiple generic manufacturers and distributors rather than a single concentrated challenger group. Generic competition can arise from manufacturers with approved ANDAs, contract manufacturers, repackagers, and pharmacy-compounding channels.

A reliable current list of active ANDA holders requires a current FDA Orange Book and Drugs@FDA review. Market participants can change through product discontinuations, acquisitions, supply transfers, and label updates. No single company controls the standard amitriptyline hydrochloride tablet market.

The competitive threat to a new formulation would likely come from:

• Generic manufacturers with existing amitriptyline API and tableting capability
• Contract development and manufacturing organizations
• Compounding pharmacies offering customized liquids
• Manufacturers of adjacent neuropathic-pain and migraine products
• 505(b)(2) developers pursuing alternative delivery systems

How strong is the patent estate for amitriptyline hydrochloride?

The patent estate is weak for the base tablet and potentially moderate for a technically differentiated formulation.

Product concept	Patent strength potential	Main vulnerability
Conventional immediate-release tablet	Low	Routine excipient combinations
Lactose-free tablet	Low	Predictable substitution
Dye-free tablet	Low	Limited technical contribution
Taste-masked ODT	Moderate	Obviousness and weak taste data
Alcohol-free oral solution	Moderate	Known solvents, buffers, and preservatives
Sustained-release product	Moderate to high	Prior art and clinical equivalence burden
Sprinkle capsule with coated particles	Moderate	Enablement and administration variability
Device-linked liquid product	Moderate	Design-around risk
Fixed-dose combination	Moderate to high	Combination obviousness and clinical proof

The strongest patent position would require a formulation with an unexpected property: superior stability, clinically meaningful pharmacokinetic control, strong taste masking without delayed release, or improved administration performance.

What commercial opportunities exist for amitriptyline hydrochloride?

The commercial opportunity is a lifecycle-management opportunity, not a molecule-discovery opportunity.

Highest-priority opportunities

1. Alcohol-free, sugar-free oral liquid
   Targets titration, dysphagia, pediatric prescribing, and institutional use.

2. Taste-masked ODT
   Targets older adults and patients with swallowing difficulty.

3. Low-dose, easy-split tablet portfolio
   Supports titration and may improve prescribing flexibility.

4. Dye-free and lactose-free tablets
   Addresses formulary preferences and excipient-sensitive patients.

5. Sprinkle or feeding-tube formulation
   Targets specialized administration needs.

6. Modified-release product
   Offers the greatest technical differentiation but carries the highest development and regulatory risk.

Commercial success would depend on reimbursement, pharmacy substitution rules, supply continuity, unit economics, and evidence supporting the claimed patient benefit. A premium price is unlikely for a conventional tablet with cosmetic excipient changes.

How does amitriptyline compare with competing drugs?

Amitriptyline competes with generic nortriptyline, desipramine, imipramine, duloxetine, venlafaxine, gabapentin, pregabalin, and other products used for depression, neuropathic pain, migraine, or sleep-related symptoms.

Attribute	Amitriptyline	Newer competing therapies
Acquisition cost	Usually low	Often higher, depending on product
Anticholinergic burden	High	Often lower
Sedation	Common	Variable
Generic availability	Extensive	Extensive for many products
Liquid formulation opportunity	Meaningful	Varies by competitor
Patient differentiation	Administration and tolerability	Often clinical profile or safety
Patent leverage	Weak for standard tablet	Varies by product and formulation

An excipient upgrade cannot eliminate amitriptyline's pharmacologic liabilities. The most credible commercial positioning is improved administration, dose flexibility, or adherence.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are manageable for conventional tablets but increase sharply for liquids, ODTs, and multiparticulates.

Key barriers include:

• Reliable low-dose content uniformity
• API particle-size control
• Moisture protection
• Taste-masking reproducibility
• Preservative efficacy
• Container-closure compatibility
• Robust dissolution across strengths
• Packaging that protects ODTs from humidity
• Validated dosing devices for liquids
• Scale-up from laboratory granulation to commercial production

Supply-chain risk is also relevant. A formula dependent on a single grade of mannitol, crospovidone, flavor, coating polymer, or colorant may be vulnerable to shortages. A dual-source excipient strategy can reduce disruption risk, but alternative suppliers must be qualified for functionality, impurity profile, and regulatory comparability.

What generic launch scenarios exist?

Conventional tablet launch

This is the fastest and lowest-risk route but has weak margin potential. Success requires competitive cost, reliable supply, and broad wholesaler or institutional access.

Differentiated liquid launch

A liquid can command better economics if it solves taste, dosing, or administration problems. The likely regulatory route depends on whether the product is pharmaceutically equivalent to an existing approved product or relies on a new formulation and clinical bridge.

505(b)(2) formulation launch

A 505(b)(2) application may be appropriate for a novel dosage form that relies partly on FDA findings for an existing amitriptyline product. The applicant would need to establish the product's quality, safety, efficacy, and reliance strategy. Any exclusivity would be tied to the approved innovation, not the old active ingredient.[5]

Compounding displacement strategy

A commercially manufactured, FDA-approved liquid could displace some pharmacy-compounded use by offering standardized concentration, validated stability, labeled instructions, and consistent packaging. This opportunity is strongest where compounded products have variable availability or limited taste acceptability.

Key Takeaways

• Amitriptyline hydrochloride is a mature generic small molecule with no meaningful remaining composition-of-matter exclusivity.
• Standard tablets have low patent value and intense price competition.
• The best excipient opportunities are patient-segmented: alcohol-free liquids, sugar-free products, taste-masked ODTs, dye-free tablets, and low-dose titration formats.
• Taste masking is the main technical challenge for liquids and ODTs.
• Modified-release and multiparticulate products offer stronger patent potential but require greater development investment.
• Biosimilar risk is not applicable because amitriptyline is a small molecule.
• Paragraph IV risk is limited for conventional tablets but could become material for a new Orange Book-listed formulation.
• Commercial value will come from administration, adherence, supply reliability, and channel differentiation rather than the active ingredient itself.
• A 505(b)(2) strategy may support a differentiated dosage form when an ANDA is not appropriate.
• Any premium product needs measurable clinical or operational value beyond lactose-free or dye-free positioning.

FAQs

Can amitriptyline hydrochloride be formulated as a pediatric liquid?

Yes. An oral liquid can support dose titration and swallowing limitations, but taste masking, preservative efficacy, stability, and dosing-device accuracy are central development requirements. Pediatric use must also account for the drug's age-related safety warnings.

Which excipient is best for taste masking amitriptyline?

No single excipient is universally best. Effective systems generally combine sweeteners, flavors, viscosity control, pH adjustment, and polymeric or particulate taste masking. The final choice depends on concentration, dosage form, target population, and release profile.

Is an amitriptyline hydrochloride ODT commercially attractive?

Potentially. An ODT can address dysphagia and adherence barriers, but commercial value depends on rapid disintegration, acceptable mouthfeel, low friability, moisture-protective packaging, and effective bitterness control.

Can a new amitriptyline formulation receive patent protection?

Yes, if the formulation is novel, nonobvious, adequately described, and supported by reproducible technical advantages. Routine excipient substitutions are less likely to produce durable patent protection.

Does amitriptyline hydrochloride have biosimilar competition?

No. Amitriptyline hydrochloride is a chemically synthesized small molecule. Competition occurs through generic drugs, reformulations, and compounded products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2023). Amitriptyline hydrochloride tablet prescribing information. DailyMed.

2. National Library of Medicine. (2024). DailyMed: Amitriptyline hydrochloride product labeling and inactive ingredients. U.S. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2009). Guidance for industry: 180-day exclusivity when multiple ANDAs are submitted on the same day. FDA.

5. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.